Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Change in Accured Expenses (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Change in Accured Expenses data on record, last reported at -$15.0 million in Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 241.86% to -$15.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$8.3 million, a 74.05% increase, with the full-year FY2025 number at $2.3 million, up 106.46% from a year prior.
  • Change in Accured Expenses reached -$15.0 million in Q1 2026 per PCVX's latest filing, down from $6.2 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for PCVX hit a ceiling of $6.2 million in Q4 2025 and a floor of -$21.7 million in Q3 2024.
  • A 5-year average of -$2.4 million and a median of -$737000.0 in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 281.9% in 2023, then plummeted 1239.91% in 2024.
  • Tracing PCVX's Change in Accured Expenses over 5 years: stood at -$2.3 million in 2022, then skyrocketed by 281.9% to $4.1 million in 2023, then plummeted by 325.59% to -$9.3 million in 2024, then skyrocketed by 166.81% to $6.2 million in 2025, then plummeted by 341.21% to -$15.0 million in 2026.
  • Business Quant data shows Change in Accured Expenses for PCVX at -$15.0 million in Q1 2026, $6.2 million in Q4 2025, and -$2.5 million in Q3 2025.